top of page
Browse by category
Search
EMA reviewing data after reports of suicidal thoughts and thoughts of self-harm after taking GLP-1a
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) is reviewing data on the risk of suicidal...
Novo Nordisk to protect US patients from unlawful sales of non-FDA approved ‘semaglutide medicines’
Novo Nordisk is taking multiple actions to protect US patients from the unlawful marketing and sales of non-FDA approved counterfeit and...
NHS England to prescribe semaglutide, potentially expanding access to tens of thousands of people
NHS doctors in England could soon be allowed to prescribe more people with Wegovy (semaglutide) under a new pilot scheme. It is hoped the...
AOMs help patients manage postsurgical weight recurrence
Anti-obesity medications, including semaglutide (Ozempic and Wegovy), can effectively help patients manage weight regained after...
FDA warns against using compounded semaglutide
The FDA has received adverse event reports after patients used compounded semaglutide for type 2 diabetes and weight loss. Drug...
SURMOUNT-5: Tirzepatide and semaglutide go head-to-head in battle of weight loss drugs
Eli Lilly and Company has registered its intent to carry out a Phase 3b clinical trial that will see the company’s tirzepatide (Mounjaro)...
NICE recommends semaglutide should be made available in specialist NHS services
The UK’s regulatory body, NICE, has recommended the use of semaglutide (also called Wegovy or Ozempic) alongside a reduced-calorie diet...
Browse by tag
bottom of page